ADAP
Adaptimmune Therapeutics
ADAP
ADAP
80 hedge funds and large institutions have $144M invested in Adaptimmune Therapeutics in 2024 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 22 increasing their positions, 15 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
5% more funds holding
Funds holding: 76 → 80 (+4)
0.15% less ownership
Funds ownership: 10.04% → 9.89% (-0.15%)
4% less capital invested
Capital invested by funds: $150M → $144M (-$5.89M)
Holders
80
Holding in Top 10
2
Calls
$107K
Puts
$6K
Top Buyers
| 1 | +$1.55M | |
| 2 | +$1.2M | |
| 3 | +$906K | |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$359K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$95K |
Top Sellers
| 1 | -$2.28M | |
| 2 | -$1.7M | |
| 3 | -$1.23M | |
| 4 |
AI
Acuitas Investments
Seattle,
Washington
|
-$528K |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$494K |